B-082 Evaluation of Minimal Residual Disease Detection Modalities in Multiple Myeloma: SPEP, Immunofixation, NGS, and Flow Cytometry
Minimal residual disease (MRD) detection is increasingly central to treatment decisions in multiple myeloma (MM). Current IMWG guidelines recommend bone marrow–based MRD assessment using either next-generation sequencing (NGS) or flow cytometry, yet discordant results between these modalities create interpretive...